Welcome
Support Centre
19 November 2008 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Medical Research Council/ European Blood and Marrow Transplant Prospective Randomised Trial of Autograft in Chronic Myeloid Leukaemia (CML)
ISRCTN ISRCTN53369512
ClinicalTrials.gov identifier
Public title Medical Research Council/ European Blood and Marrow Transplant Prospective Randomised Trial of Autograft in Chronic Myeloid Leukaemia (CML)
Scientific title
Acronym N/A
Serial number at source MRC CML 2000 (IVa)
Study hypothesis Not provided at time of registration.
Ethics approval Not provided at time of registration.
Study design Randomised controlled trial.
Countries of recruitment United Kingdom
Disease/condition/study domain Leukaemia (chronic)
Participants - inclusion criteria 1. Newly diagnosed Ph-positive and/or breakpoint cluster region (BCR)-abelson (ABL) positive CML
2. Aged 15-65
3 .Chronic phase disease
4. No contraindication to the collection of peripheral blood progenitor cells before commencing treatment
5. No major organ impairment
6. No pregnancy
Participants - exclusion criteria Not provided at time of registration.
Anticipated start date 01/10/1996
Anticipated end date 30/10/2001
Status of trial Completed
Patient information material
Target number of participants Not provided at time of registration.
Interventions Two Arms:

1. Control: Interferon (IFN) Starting dose 3 x 10(6) units x 3/week escalating to 5 x 10(6) units/m(2) daily. Adjusted to maintain leukocyte count 2-4 x 10(9)/l. Use of hydroxyurea and/or ara-c optional.

2. Investigational: Mobilised or straight autograft, followed by IFN (+/- Ara-c).
Primary outcome measure(s) Not provided at time of registration.
Secondary outcome measure(s) Not provided at time of registration.
Sources of funding 1. European Bone Marrow Transplantation Group
2. Medical Research Council (UK)
Trial website
Publications
Contact name Dr  -  -
  Address UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
  City/town London
  Zip/Postcode NW1 2DA
  Country United Kingdom
  Tel +44 (0) 20 7670 4723
  Fax +44 (0) 20 7670 4818
  Email register@ctu.mrc.ac.uk
Sponsor Medical Research Council (MRC) (UK)
  Address 20 Park Crescent
  City/town London
  Zip/Postcode W1B 1AL
  Country United Kingdom
  Tel +44 (0)20 7636 5422
  Fax +44 (0)20 7436 6179
  Email clinical.trial@headoffice.mrc.ac.uk
  Sponsor website: http://www.mrc.ac.uk
Date applied 19/08/2002
Last edited 10/09/2007
Date ISRCTN assigned 19/08/2002
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central